Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies - CA239-0071
Mis à jour: 13 mai, 2026 | ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Emplacement(s)
Recruiting
Inclusion Criteria: - Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit. - Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF. Exclusion Criteria: - Participant is not eligible for study treatment per the parent study eligibility criteria. - Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study. - Participants not receiving clinical benefit from parent study drug as assessed by the investigator. Other protocol defined inclusion/exclusion criteria applies.
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales
